Biopharma and dating apps may seem an unlikely pairing, but both face the same challenge: matching the right people with the right opportunity. Dating platforms have become very good at it, using algorithms, user experience design, and behavioral insight to create connections that last. Clinical trials, meanwhile, still struggle with outdated recruitment methods, low engagement, and high dropout rates. If biopharma patient recruitment borrowed some of what dating apps do to attract and keep users, participation and completion could look very different.
Finding the Right Match
Dating apps thrive on precision. They use data-driven matching to connect individuals based on compatibility, interests, and behavior. The process is simple, personalized, and designed to keep users engaged. Biopharma, on the other hand, still relies on broad outreach efforts, hoping that the right people will somehow find their way into trials.
The reality is that clinical trials need a smarter approach. Biopharma patient recruitment can borrow from the way dating apps refine what they show each user: help people see, in plain language, whether a study may be relevant to them before they contact a site. Eligibility is still decided by the study team, but a person who understands the study first is far less likely to become a screen failure or an early dropout than someone reached by mass outreach.
Another lesson lies in user experience. Dating apps make the process simple: swipe, match, chat. Clinical trial platforms are often cumbersome, filled with dense medical terminology and unclear participation steps. Streamlining trial portals and simplifying the first steps can create a more patient-friendly experience, increasing the likelihood of retention.
Trial platforms could also benefit from recommendation engines similar to those used in dating apps. Instead of making people sift through complex lists of available trials, intelligent algorithms could suggest relevant studies based on a person’s profile, reducing the number of people who reach a site only to find the study was never a realistic option for them.
Clinical Trial Engagement That Lasts
In dating, engagement isn’t just about making a match; it’s about keeping interest alive. A well-designed dating app knows how to bring users back, whether through push notifications, curated recommendations, or interactive content. Clinical trials, however, often lose engagement after the initial sign-up phase, with patients dropping out due to lack of communication, long wait times, or unclear expectations.
This is where clinical trial engagement needs a rethink. Regular updates, personalized reminders, and ongoing patient support can make the process feel less like a one-time transaction and more like an ongoing relationship. Just as dating apps keep users engaged with relevant content, biopharma can maintain interest through educational resources, trial updates, and direct interaction with researchers.
Patients also need reassurance that their participation matters. Just as dating apps offer validation through matches and messages, clinical trials can improve retention by showing patients how their involvement contributes to medical advancements. Transparency around trial progress, patient impact stories, and real-time feedback loops can turn passive participants into active trial advocates.
Recognition can further support retention. While dating apps use gamification elements like badges and streaks to encourage activity, clinical trials could adopt patient recognition programs, milestone updates, and fair reimbursement for the time and travel that follow-up visits require, always within the limits ethics committees set so that no one feels pressured to stay.
Reducing the Fear of Commitment
Signing up for a clinical trial can feel like a long-term commitment with unknown risks. The same could be said for dating. Yet dating apps have made it easy to explore connections without feeling locked in. They allow users to browse options, engage at their own pace, and opt out when necessary. Clinical trials, by contrast, often require an immediate commitment without fully addressing patient concerns or hesitations.
Creating a low-pressure entry point could make a difference. Pre-trial engagement, such as virtual consultations, interactive Q&A sessions, and trial previews, could help people make informed decisions without feeling rushed. Giving potential participants time to understand a study before they are asked to enroll is what readiness means in practice, and it is where avoidable screen failures and early withdrawals are prevented.
Transparency is another factor. Dating apps set clear expectations by showing user profiles, outlining compatibility scores, and providing insights into potential matches. Clinical trials could adopt a similar approach by offering clear, digestible information about study goals, risks, time commitments, and potential outcomes. This kind of openness builds trust and reduces uncertainty.
Additionally, offering a phased entry into trials could help people ease into participation. Just as dating apps allow users to communicate before meeting in person, clinical trials could introduce pre-trial education sessions or simple self-reflection tools that help people think through whether a study fits their health and their life before full enrollment.
Personalization Drives Participation
Dating apps succeed because they make users feel like the experience is tailored just for them. Every match, message, and notification is based on user data, ensuring relevance and engagement. Clinical trials, on the other hand, often fail to create this sense of personalization. Generic recruitment emails, rigid eligibility criteria, and one-size-fits-all outreach efforts fail to connect with people on an individual level.
A shift toward personalized recruitment could change this. Using patient data to create customized trial recommendations, offering flexible participation options, and providing individualized support can make clinical research more approachable. People are more likely to enroll and stay engaged when they feel the trial is designed with their specific needs in mind.
Technology can play a crucial role here. Mobile apps, AI-driven chatbots, and digital health tracking tools can make trial participation feel integrated into daily life rather than bolted on. Participants should receive reminders, progress updates, and personalized check-ins that reinforce their importance in the study.
Biopharma could also explore interactive content strategies similar to dating apps, using patient-friendly quizzes, symptom trackers, or chat-based self-reflection checks that help people consider whether a study could fit their life, so the first contact with a site feels less clinical and more considered.
Rethinking the Participant Experience
The success of dating apps shows that engagement is not just about offering opportunities. It is about making those opportunities easy to understand, appealing, and rewarding. Biopharma can take the same approach. Patient recruitment should not be a last-minute scramble but a well-thought-out strategy that prioritizes user experience, personalization, and ongoing communication. By applying these principles, clinical trials can move away from outdated recruitment models and toward a system that values the participant’s understanding as much as the research itself. See what trialport does for sponsors and CROs.
About the author
Keith Berelowitz has spent more than twenty years watching clinical trials work on paper and struggle in real life. He has helped run studies, advises sponsors and CROs on how they engage with people, and chairs a UK research ethics committee, where consent forms and participant information sheets cross his desk every month. That vantage point led to one conclusion: most trial problems are not failures of science. They are failures of understanding at the moment a person decides.
He founded trialport, an AI native clinical trial navigation and decision-support platform, in the belief that technology earns its place in research only when it makes a study easier to understand and a decision easier to make. Understanding comes first. Decisions follow.